Skip to main content
Download App | About Us | About
Current Complaints | Help Center| Subscribe
MoneyWorks4Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call

Beta Drugs Ltd (BETA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BETA Pharmaceuticals & Drugs | Small Cap | Beta Drugs Share Price

BSE Share Price
Not Listed

Beta Drugs Ltd (BETA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BETA Pharmaceuticals & Drugs | Small Cap | Beta Drugs Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1,913 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹46.7
TTM Sales
₹444 Cr.
Book Value per Share
₹393.6
P/E Ratio
36.85
Lower than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
4.37
Lower than its 5-year historical median
Price to Sales (P/S)
4.31
Lower than its 5-year historical median
EV/EBITDA
18.43
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
18.78%
Outperforms industry median
Return on Capital Employed (ROCE)
19.16%
Outperforms industry median
Return on Assets (ROA)
8.77%
Outperforms industry median
Operating Profit Margin
19.7%
Outperforms industry median
Net Profit Margin
10.78%
Outperforms industry median
Gross Profit Margin
18.6%
Outperforms industry median
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
2.38%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
1.43%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-2.22%
Asset Quality
Promoter Holding
58.91%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹427 Cr.
Equity
₹11.1 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00

Beta Drugs stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Beta Drugs Ltd a good quality company?
Beta Drugs Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Beta Drugs Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Beta Drugs Ltd vs industry peers?
Beta Drugs Ltd revenue CAGR is 27.08%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Beta Drugs Ltd?
Promoters hold 58.91% of the Beta Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Beta Drugs Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 23.86% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beta Drugs Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ48.9%28.6%18.4%16.9%15.9%26.9%27.9%27.3%13.5%11.2%-
Value Creation
Index ⓘ		2.51.10.30.20.10.91.01.00.0-0.2-

Growth Parameters ⓘ
Sales ⓘ41.750.658.165.379.5125158198220225218
Sales YoY Gr.-21.4%14.8%12.5%21.7%57.1%26.5%25.2%11.4%2.4%-
Adj EPS ⓘ7.48.18.876.914.118.621.718.514.116.4
YoY Gr.-9.3%8.5%-20.2%-1.3%104.1%32%16.6%-15.1%-23.4%-
BVPS (₹) ⓘ9.736.244.755.962.876.795.4114.9127.8147.5285.8
Adj Net
Profit ⓘ		4.67.487.1714.318.821.918.614.318
Cash Flow from Ops. ⓘ4.717.17.76.111.618.810.221.21819.2-
Debt/CF from Ops. ⓘ1.70.511.50.50.40.60.37.16.8-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ20.6%23.2%12.6%2.4%
Adj EPS ⓘ7.5%15.4%-8.8%-23.4%
BVPSⓘ35.3%18.6%15.7%15.4%
Share Price - 24.6% 21.1% 1.5%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		11237.721.714.611.720.221.720.715.210.37.6
Op. Profit
Mgn % ⓘ		18.720.418.41819.320.219.81714.312.715
Net Profit
Mgn % ⓘ		11.114.513.710.88.811.411.911.18.56.48.3
Debt to
Equity ⓘ		1.40.20.20.20.10.10.10.110.90
Working Cap
Days ⓘ		99138180211196149157170187209171
Cash Conv.
Cycle ⓘ		26476373664149514649124

Valuation of Beta Drugs - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales516691116184227296362385
Operating Expenses ⓘ + 41547391141174236288309
Manufacturing Costs6810131724321926
Material Costs2733445994106149171171
Employee Cost 14781217204861
Other Costs ⓘ 6912121727344951
Operating Profit ⓘ 91218254353607576
Operating Profit Margin (%) 18.7%17.9%19.7%21.3%23.2%23.4%20.3%20.6%19.7%
Other Income ⓘ + 0001111611
Exceptional Items ⓘ 0000000-50
Interest ⓘ 1132223715
Depreciation ⓘ 2347710101317
Profit Before Tax ⓘ 7812163441495754
Tax ⓘ 0-034910121513
Profit After Tax 789122531364241
PAT Margin (%) 13.4%12.2%10.4%10.1%13.5%13.5%12.3%11.7%10.8%
Adjusted EPS (₹)7.58.99.311.624.630.436.142.041.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 3341576992123157197245
Share Capital ⓘ 8.658.659.619.619.619.619.6110.0910.14
Reserves ⓘ 2432475983113148187235
Debt +6182015171611133141
Long Term Debt3710111276127133
Short Term Debt41110459568
Minority Interest000000000
Trade Payables61314203240597181
Others Liabilities ⓘ 41217162225354435
Total Liabilities ⓘ 5083108120163204262445501

Fixed Assets

Net Fixed Assets ⓘ +1318444055636589125
Gross Block182558618299109146200
Accumulated Depreciation5814212737455775
CWIP ⓘ 1150300000
Investments ⓘ 000111000
Inventories31012162231506074
Trade Receivables14253234456379103119
Cash Equivalents 123510171929147125
Others Assets ⓘ 61314162228404757
Total Assets ⓘ 5083108120163204262445501
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 1708193023313637
PBT ⓘ 7812163441496254
Adjustment ⓘ 1522752-4-610
Changes in Working Capital ⓘ -5-9-6-4-10-20-14-19-27
Tax Paid ⓘ 000000000
Cash Flow From Investing Activity ⓘ + -11-21-15-6-22-19-14-36-51
Capex -8-21-15-6-19-18-12-37-53
Net Investments 0-00-000100
Others ⓘ -3000-2-1-312
Cash Flow From Financing Activity ⓘ + 5129-8-1-2-7118-8
Net Proceeds from Shares ⓘ 809000007
Net Proceeds from Borrowing ⓘ -16411-4-11246
Interest Paid ⓘ -1-1-3-2-2-2-3-7-15
Dividend Paid ⓘ 000000000
Others ⓘ -07-1-604-41-6
Net Cash Flow ⓘ 12-925729118-22
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)20.5721.7919.2118.6530.8528.5526.0323.9518.78
ROCE (%)19.3618.4120.7122.1736.3833.9432.7425.2319.16
Asset Turnover Ratio1.020.990.951.021.31.241.271.020.81
PAT to CFO Conversion(x)2.4300.891.581.20.740.860.860.9
Working Capital Days
Receivable Days104.30109.30114.50103.4078.5086.7087.6091.60105.10
Inventory Days20.2034.104444.6038.2042.7049.6055.2063.70
Payable Days82105113.60108.60101.30124.70121.60139161.90

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Annual reports

No annual reports available.

Concalls

No concalls available.

Beta Drugs Ltd FAQs

The current trading price of Beta Drugs on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Beta Drugs stood at ₹1,913.4 Cr

The latest P/E ratio of Beta Drugs as of 31-Dec-1969 is 105.0.

The latest P/B ratio of Beta Drugs as of 31-Dec-1969 is 6.02.

The 52-week high of Beta Drugs is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beta Drugs is ₹218 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company.

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beta Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Beta Drugs Ltd

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now